PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cedazuridine

Drugs in development · updated 30 October 2026

Cedazuridine: clinical trials and development status

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 15 September 2023

As of 30 October 2026 Cedazuridine is in 34 active clinical trials (recruiting or ongoing, phases I–III) for 21 diseases. The most advanced phase is III.

34Active trials
IIIMost advanced phase
21Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cedazuridine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII20NCT05883956
Myelodysplastic SyndromesIII12NCT05883956
Chronic myelomonocytic leukemiaIII7NCT05883956
Refractory anemia with excess of blastsII–III2NCT04256317
Hematologic DiseasesII–III1NCT04256317
LeukemiaII–III1NCT04256317
Patient preferenceIII1NCT05883956
Myeloproliferative disordersII3NCT05564390
Diffuse large B-cell lymphomaII2NCT03418038
Hodgkin lymphomaII2NCT03418038
Myelodysplastic–myeloproliferative diseasesII2NCT06661915
Acute biphenotypic leukaemiaII1NCT04975919
Chronic phase chronic myelogenous leukemiaII1NCT05007873
LymphomaII1NCT03418038
Malignant mesotheliomaII1NCT05960773
MesotheliomaII1NCT05960773
MyelofibrosisII1NCT06661915
Polycythemia veraII1NCT06661915
Thrombocythemia, EssentialII1NCT06661915
B-cell lymphomaI1NCT05272384
GATA2 deficiencyI1NCT06484062

Everything on Cedazuridine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch